ChemoCentryx

Second Quarter 2018
Financial Results Conference Call

August 9, 2018

ChemoCentryx

Forward-Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “contemplate,” “believe,” “estimate,” “predict,” “project,” “seek,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described more fully in our periodic reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 12, 2018, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. The forward-looking statements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this presentation.

This presentation also contains estimates, projections and other information concerning our industry, our business, and the markets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

Three Major Highlights

- Completed enrollment of ADVOCATE trial for avacopan in ANCA Vasculitis
- >$200 million on balance sheet at June 30, boosted by >$90 million cash receipts in first half of 2018
- Expect to launch two-arm study of avacopan in Hidradenitis Suppurative (HS), with 12 week endpoint, by end of 2018

ADVOCATE Trial Fully-Enrolled
Avacopan: First-in-Class Selective C5aR Inhibitor

- 316 patients enrolled in Phase III ADVOCATE trial
- ADVOCATE will evaluate safety and efficacy of avacopan following 52 weeks of continuous treatment:
  - Show impact of avacopan in treating active ANCA Vasculitis
  - Test durability of this clinical benefit (one of the major problems with current Standard of Care)
- Top-line data expected in Q4 2019

ChemoCentryx

A New Frontier: Orphan Dermatological Disease

- First target: avacopan in Hidradenitis Suppurativa (HS), a neutrophil-driven disease
- HS causes keloids, contractures, immobility
- Avacopan selectively targets C5aR, implicated in HS
- Potential for greater efficacy over other approaches
- Planning to launch large clinical trial in 2018

ChemoCentryx

C3 Glomerulopathy (C3G)

Orphan Disease with No Approved Therapy

- C3G characterized by uncontrolled activation of the complement system leading to complement protein deposition in the kidney
- Disease often strikes young; kidney transplant and relapse often occurs
- No FDA-approved therapies
- First phase of 22 patients taking avacopan plus 22 patients on placebo nearing 50% enrolled
- Amendment filed to add 44 C3G patients who screen below complement level qualification threshold for first phase

ChemoCentryx

Focal Segmental Glomerulosclerosis (FSGS)

- In FSGS, proteinuria (protein in urine) destroys kidney function
- No approved treatments in FSGS, and disease returns in 30-40% of transplant cases
- Previous clinical trial with CCX140 shows it significantly lowered proteinuria (a one year long Phase II trial of diabetic nephropathy)
- CCXI clinical trials underway in two sub-populations of FSGS

5,400 new cases in U.S.
1,000 kidney transplants / year
In 30-40% of transplant patients, FSGS returns

CCR2 Inhibition Increased Podocyte Density in 'FSGS' Mice



- Brown 'spots' are cell nuclei detected with an antibody to WT-1, a podocyte nuclei protein
- Panels show cross section of a kidney glomerulus (roughly circular in this 2 dimensional view)
- The right panel is a typical glomeruli from an FSGS mouse treated with CCR2 inhibitor for 2 weeks; versus placebo treatment on left

ChemoCentryx

Q2 2018 Financial Results – June 30, 2018

- Cash and investments - $202 million
- Total shares outstanding – 50.3 million
- Consolidated statement of operations –

	Three Months Ended June 30,	
	2018	2017
	(unaudited)	
	(in thousands, except per share data)	
Condensed Consolidated Statements of Operations Data:		
Revenue:		
Collaboration and license revenue	$ 15,022	$ 8,937
Total revenue	15,022	8,937
Operating expenses:		
Research and development	17,759	14,329
General and administrative	4,748	4,184
Total operating expenses	22,507	18,513
Loss from operations	(7,485)	(9,576)
Total other income, net	611	336
Net loss	$ (6,874)	$ (9,240)

Key Takeaways for the Quarter

- ADVOCATE Phase III trial enrollment complete
- Other late-stage trials underway
  - In process of doubling planned size of trial for avacopan in C3G
  - Launched trials of CCX140 in two sub-populations of primary FSGS
- Expanded commercial alliance with Vifor to include China
  - CCXI retains US rights, receive royalties from Vifor on potential ex-U.S. net sales
- Expanding into orphan dermatological disease:
  - Expect to launch clinical development of avacopan in HS in 2018
- >$200MM on balance sheet; >$90 MM cash receipts in first half